1 Introduction The global prevalence of non-alcoholic fatty liver disease (NAFLD) has shown a consistent upward trend in recent decades, with current estimates indicating an overall prevalence of 30.05% ( In a pivotal 2023 consensus statement, international liver associations proposed redefining disease terminology, replacing NAFLD with metabolic dysfunction-associated steatotic liver disease (MASLD) and NASH with metabolic dysfunction-associated steatohepatitis (MASH) ( MASLD pathogenesis involves complex interactions among multiple pathological processes, including excessive fatty acid accumulation, dysregulated inflammatory responses, oxidative stress, and insulin resistance
Can-C contains a unique form of N-acetyl-carnosine which has been shown in animal and clinical trials to help reduce, slow and even reverse the occurrence of senile cataract
Hadgis uses a 3D digital model of the patient's teeth to create a representation of the final result in the software
The NF-B pathway is a complex signaling cascade that regulates the expression of various genes involved in immunity, inflammation, and cell survival (96)
Switching GLP-1s Stopping GLP-1s Wraparound support in weight loss Inappropriate access to GLP-1s What are GLP-1s
doi: 10.1007/BF03261931
